Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash & Equivalents (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Cash & Equivalents for 3 consecutive years, with $42.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Cash & Equivalents rose 670.01% year-over-year to $42.1 million, compared with a TTM value of $42.1 million through Sep 2024, up 670.01%, and an annual FY2023 reading of $9.1 million, down 77.62% over the prior year.
  • Cash & Equivalents was $42.1 million for Q3 2024 at Oramed Pharmaceuticals, down from $84.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $84.8 million in Q2 2024 and bottomed at $5.5 million in Q3 2023.
  • Average Cash & Equivalents over 3 years is $29.3 million, with a median of $28.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 83.53% in 2023, then skyrocketed 1152.45% in 2024.
  • Year by year, Cash & Equivalents stood at $40.5 million in 2022, then plummeted by 77.62% to $9.1 million in 2023, then skyrocketed by 364.98% to $42.1 million in 2024.
  • Business Quant data shows Cash & Equivalents for ORMP at $42.1 million in Q3 2024, $84.8 million in Q2 2024, and $18.6 million in Q1 2024.